Skip to main content
FOCIS 2025 Main banner
Final Program


Final Program

Kerry Reynolds, MD

Assistant Professor
Massachusetts General Hospital
Boston, Massachusetts, United States

Dr. Kerry Reynolds, an oncologist at Mass General Cancer Center and Assistant Professor of Medicine at Harvard Medical School, leads the nation’s first Severe Immunotherapy Complications (SIC) Service. This groundbreaking program ensures that every hospitalized patient suspected of immune-related adverse events (irAEs) from immunotherapy receives expert care from a dedicated oncologistand subspeciaty team. Since its inception, the SIC Service has expanded to include over 60 clinicians and researchers across 19 specialties. Dr. Reynolds joined Harvard Medical School in 2014 after completing her residency, chief residency, and oncology fellowship at Massachusetts General and Dana-Farber/Partners Cancer Care. In addition to providing clinical care, she supervises and educates trainees, manages inpatient cancer services, and conducts pioneering research on irAEs. Her work aims to improve outcomes for patients receiving immunotherapy by identifying irAE predictors and biomarkers, refining management practices, and uncovering the mechanisms driving irAEs. Collaborating with Dr. Alexandra-Chloe Villani, Dr. Reynolds leads efforts to systematically collect and analyze blood and tissue samples from affected patients, leveraging cutting-edge technologies to advance understanding and treatment of these toxicities.

Disclosure information not submitted.

Presentation(s):